The biggest winner in health care, and possibly on the entire market, was MannKind (NASDAQ:MNKD) today, up an astonishing 73% after the advisory committee reviewing its inhalable insulin Afrezza to make its recommendation to the FDA for or against, shocked the world by voting overwhelmingly in favor of the drug. The final votes were 13-1 in support of its type 1 diabetes indication, and 14-0 for type 2 diabetes.

In this video, Motley Fool health-care analyst David Williamson breaks down just how much of a massive win this is for the company. He discusses the long road MannKind has traveled toward commercialization, and the further questions and concerns he has, now that FDA approval looks incredibly likely.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.